Search the Newsreel

Iovance Sets Aug. 6 Webcast to Discuss Second-Quarter Results

Iovance Biotherapeutics (NASDAQ: IOVA) announced it will host a conference call and live audio webcast on Thursday, August 6, 2026, at 8:30 a.m. ET to report its second quarter 2026 financial results and provide corporate updates. Investors can access the live or archived webcast …

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced it will host a conference call and live audio webcast on Thursday, August 6, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide corporate updates. The company is a biotechnology firm focused …

Iovance Biotherapeutics Inc (IOVA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Iovance Biotherapeutics Inc (IOVA), noting its current score of 4.11 and its ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 0.74, indicating less volatility than the S&P 500, and presents …

Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should Know

Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth

Wall Street expects a year-over-year increase in earnings on higher revenues when Bioventus (BVS) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …

Bioventus schedules Aug. 5 call to discuss second-quarter results

Iovance Biotherapeutics Inc (IOVA) Institutional Confidence

Iovance Biotherapeutics Inc (IOVA) has an institutional shareholding score of 5.00, placing it 132nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 69.13%, marking an 11.55% increase quarter-over-quarter. MHR Fund Management LLC is listed as the largest …

BlackRock (IOVA holder) reports 33.4M Iovance Biotherapeutics shares, a 7.5% stake

BlackRock, Inc. has reported a 7.5% stake in IOVANCE BIOTHERAPEUTICS, INC. (IOVA), beneficially owning 33,366,587 shares as of June 30, 2026. The firm holds sole voting power over 32,842,318 shares and sole dispositive power over all 33,366,587 shares, with no single underlying client holding …

BlackRock (BVS) discloses 3.4M-share, 5.02% passive stake in Bioventus

BlackRock, Inc. has disclosed a passive ownership stake of 5.02% in Bioventus Inc.'s Class A stock, totaling 3,404,523 shares. This information was reported via a Schedule 13G filing, indicating BlackRock holds sole voting power over 3,350,552 shares and sole dispositive power over all 3,404,523 …

IOVA|Iovance Biotherapeutics Inc|Price:4.990|Chg%:-0.140

Iovance Biotherapeutics Inc. is a commercial biotechnology company focused on developing and delivering novel tumor-infiltrating lymphocyte (TIL) therapies for cancer patients. Their key product, Amtagvi, is an autologous T cell immunotherapy for unresectable or metastatic melanoma, used in conjunction with Proleukin. The company is …

Iovance Biotherapeutics Inc (IOVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Iovance Biotherapeutics Inc (IOVA), noting that some detailed business segment data has not yet been disclosed by the company. It highlights that the vast majority of the company's revenue, $259.01 million (98.30%), is generated in the United …

Iovance Biotherapeutics Inc (IOVA) Income Statement: Quarterly and Annual Data

This article provides detailed quarterly and annual income statement data for Iovance Biotherapeutics Inc (IOVA), including metrics such as total revenue, cost of revenue, operating expenses, R&D expenses, operating profit, and net income. It also includes frequently asked questions about how to interpret the …

Iovance Biotherapeutics Inc Revenue Breakdown – MIL:1IOVA

Iovance Biotherapeutics Inc (MIL:1IOVA) generated 224.35 million EUR in revenue last year, with its Autologous Tumor Infiltrating Lymphocyte Cell Therapies segment being the primary contributor. The United States was the leading geographical source of revenue for the company. This marks an increase from the …

Iovance Biotherapeutics Inc (IOVA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Iovance Biotherapeutics Inc (IOVA), with its current earnings forecast score being 7.80. Analysts have set an average price target of $9.00 for IOVA, with a strong buy consensus based on 10 analysts. The company also has an …

Iovance Biotherapeutics Market Sentiment

The article provides an overview of market sentiment for Iovance Biotherapeutics (IOVA), detailing analyst consensus, short interest, options flow, and recent analyst actions. Key signals suggest a "Buy" consensus from analysts, declining short interest, and a bullish options flow. The report also includes a …

Why Is Ion Video (ASX:IOV) in Focus Following Its Latest Operational Update?

Iovance Biotherapeutics stock hits 52-week high at $5.64

Iovance Biotherapeutics Inc. (IOVA) stock reached a new 52-week high of $5.64, demonstrating a 75% return over the past year and substantial gains in recent months. Despite a Q1 2026 earnings miss, the company's valuation appears undervalued according to InvestingPro, with significant revenue growth. …

Iovance Biotherapeutics (IOVA) Stock Looks Fully Priced Despite Strong 117% Returns

Despite a significant 117.5% return year-to-date, Iovance Biotherapeutics (IOVA) stock appears to be fully priced, according to valuation checks and current trading multiples. While its P/S multiple of 8.6x is below the broader biotech industry average, it is considered overvalued relative to its estimated …

Should Value Investors Buy Bioventus (BVS) Stock?

Bioventus (BVS) Upgraded to Buy: Here's Why

Ion Video (ASX:IOV) Shares Drop 13.92%: What Pressured the Technology Stock?

Why Did IOVA Stock Gain Pre-Market Today?

Iovance Biotherapeutics (IOVA) stock gained over 5% in pre-market trading due to encouraging early results from a pilot study of its tumor-infiltrating lymphocyte therapy, lifileucel, for aggressive soft tissue sarcomas. The company also reported strong fourth-quarter earnings with $65 million in Amtagvi revenue, and …

Iovance Biotherapeutics (NASDAQ:IOVA) shares jump 18% as Amtagvi sales test approaches

Iovance Biotherapeutics (NASDAQ:IOVA) shares surged 18% due to investor focus on the upcoming sales performance of its drug Amtagvi. The company gained approximately $344 million in equity value last week, nearing its full-year revenue guidance midpoint. Management anticipates significant revenue growth for Amtagvi in …

Swedish Orphan Biovitrum AB (BIOVF) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Revenue Growth: 29% at constant exchange rates. Adjusted EBITDA Margin: 35% for Q2. Total Net Sales: Just under SEK7.8 billion for the quarter. Geographic Revenue Growth: North America 33%, International markets 45%, Europe 23%. Product Performance: Strong contributions …

Iovance Gives 17 New Employees Options That Vest Over 3 Years

Iovance Biotherapeutics (NASDAQ: IOVA) granted inducement stock options covering 139,930 shares to 17 new non-executive employees on July 16, 2026. The options have an exercise price of $4.66 per share, equal to the closing price on the grant date, and vest over a three-year …

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics, Inc. announced the grant of inducement stock options for 139,930 shares to seventeen new non-executive employees on July 16, 2026. These awards were made under the company's Amended and Restated 2021 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock …

Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks

Bioventix Plc Actuals & Estimates (LSE:BVXP)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Why Iovance Biotherapeutics (IOVA) Is Up 5.7% After AMTAGVI-Driven Q1 Revenue Jump And Share Plan

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance (IOVA) Q1 2026 Earnings Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?